In the BioHarmony Drug Report Database

"Preview" Icon

Migalastat

Galafold (migalastat) is a small molecule pharmaceutical. Migalastat was first approved as Galafold on 2016-05-25. It is used to treat fabry disease in the USA. It has been approved in Europe to treat fabry disease. It is known to target lysosomal alpha-glucosidase. Galafold’s patents are valid until 2038-05-30 (FDA).

 

Trade Name

 

Galafold
 

Common Name

 

migalastat
 

ChEMBL ID

 

CHEMBL110458
 

Indication

 

fabry disease
 

Drug Class

 

Enzyme inhibitors

Image (chem structure or protein)

Migalastat structure rendering